Espra 40mg Tablet (Esomeprazole 40mg)

Description

Espra 40mg Tablet (Esomeprazole 40mg) — Comprehensive Clinical Guide

Overview

Espra 40mg Tablet contains Esomeprazole Magnesium 40mg, the S-enantiomer of omeprazole and one of the most potent proton pump inhibitors (PPIs) available in clinical practice. Prescribed for the management of gastroesophageal reflux disease (GERD), erosive oesophagitis, peptic ulcer disease, and Zollinger-Ellison syndrome, Espra 40mg provides powerful, sustained gastric acid suppression with a pharmacokinetic profile optimised for consistent, predictable therapeutic outcomes.

Esomeprazole’s development as a single enantiomer drug represented a significant step in PPI pharmacology. The S-enantiomer is metabolised more slowly through the liver than racemic omeprazole, resulting in higher systemic bioavailability, more consistent plasma drug levels, and superior acid-suppressive efficacy in head-to-head clinical trials. These pharmacokinetic advantages translate to improved rates of erosive oesophagitis healing and greater GERD symptom control in clinical practice.

About the Active Ingredient: Esomeprazole

Esomeprazole is the optical S-isomer of omeprazole and was developed to address limitations of the racemic parent compound, particularly variability in acid suppression between patients. The R-isomer of omeprazole is metabolised much more rapidly by CYP2C19, resulting in lower plasma concentrations and reduced efficacy in extensive metabolisers of this enzyme. By isolating the S-enantiomer, esomeprazole achieves higher and more consistent plasma levels across the population of CYP2C19 phenotypes.

Pharmacokinetically, esomeprazole demonstrates an area under the concentration-time curve (AUC) approximately twice that of omeprazole at equivalent doses, explaining its superior acid-suppressive capacity. The drug undergoes hepatic metabolism via CYP2C19 and CYP3A4, with a terminal half-life of approximately 1–1.5 hours, though its pharmacodynamic effect (proton pump inhibition) far outlasts its plasma half-life due to irreversible covalent binding to the enzyme.

Mechanism of Action

Esomeprazole, like all PPIs, is a prodrug that requires acid activation to exert its pharmacological effect. Following oral absorption and entry into the systemic circulation, esomeprazole diffuses into the secretory canaliculi of gastric parietal cells, where it encounters the highly acidic environment necessary for its conversion to the active sulfenamide form.

This reactive sulfenamide covalently binds to specific cysteine residues (predominantly Cys813 and Cys892) on the alpha-subunit of the H+/K+-ATPase enzyme — the proton pump responsible for the final step in gastric acid secretion. By forming a stable disulfide bond with these residues, esomeprazole permanently inactivates the pump molecule. Acid secretion from that particular pump can only resume once new enzyme molecules are synthesised — a process taking 18–24 hours.

This mechanism explains several key clinical characteristics of esomeprazole: the 3–5 day lag to maximum effect (as existing pumps are progressively inhibited), the importance of pre-meal dosing (when the most pumps are active and available for inhibition), and the sustained acid suppression maintained throughout the day and night.

Clinical Indications

Erosive Reflux Oesophagitis: Esomeprazole 40mg is among the most effective PPIs for healing erosive oesophagitis. In landmark clinical trials including the EXPO and EXPO2 studies, esomeprazole 40mg demonstrated significantly higher healing rates compared to omeprazole 20mg at both 4 and 8 weeks, particularly in patients with more severe grades of oesophagitis (Los Angeles Grade C and D).

GERD Symptom Control: Esomeprazole 40mg effectively controls both typical reflux symptoms (heartburn, regurgitation) and atypical manifestations (chronic cough, laryngitis, chest pain). Sustained acid suppression reduces the acid contact time in the oesophagus and protects vulnerable squamous epithelium from injury.

Peptic Ulcer Disease: Used as monotherapy for gastric and duodenal ulcers not caused by H. pylori or in combination with antibiotics for H. pylori eradication. PPIs are essential components of modern H. pylori eradication protocols because the elevated gastric pH they maintain dramatically improves the bactericidal efficacy of clarithromycin, amoxicillin, and metronidazole.

Zollinger-Ellison Syndrome: Gastrinoma-induced acid hypersecretion requires aggressive acid suppression, and esomeprazole at higher doses is effective for controlling acid output and preventing complications in this rare but serious condition.

Prevention of NSAID-Induced Gastric Ulcers: Co-prescription with NSAIDs in patients at elevated GI risk (elderly, prior ulcer history, concurrent corticosteroid or anticoagulant use) significantly reduces the incidence of NSAID-related gastric and duodenal ulcers and their complications.

Stress Ulcer Prophylaxis: In intensive care settings, esomeprazole IV (Nexpro IV) is used to prevent stress-related mucosal bleeding in critically ill patients.

Dosage and Administration

The recommended adult dose of Espra 40mg for acute GERD treatment and erosive oesophagitis is one 40mg tablet once daily for 4–8 weeks, taken 30–60 minutes before the first meal. For maintenance of healed oesophagitis and symptom control, esomeprazole 20mg once daily may be sufficient after initial healing is confirmed.

For H. pylori eradication, esomeprazole 20mg or 40mg twice daily is used as part of standard triple therapy (with clarithromycin 500mg and amoxicillin 1000mg, each twice daily) for 7–14 days. Quadruple therapy protocols are used in regions with high clarithromycin resistance.

Tablets must be swallowed whole without crushing, chewing, or breaking, as the enteric coating protects the acid-labile drug. For patients unable to swallow tablets, the capsule contents can be mixed with non-carbonated water or apple juice (not appropriate for all formulations — check specific product instructions).

Who Should Use Espra 40mg

Espra 40mg is indicated for adults with documented GERD, erosive oesophagitis (confirmed by endoscopy), active gastric or duodenal ulcers (with or without H. pylori), Zollinger-Ellison syndrome, and those requiring long-term NSAID therapy with GI risk factors. It is particularly useful in patients who have not achieved adequate acid suppression with lower-dose PPIs or those with severe or Grade C/D oesophagitis requiring maximal acid control.

Who Should Not Use Espra 40mg

Espra 40mg is contraindicated in patients with hypersensitivity to esomeprazole, other PPI agents, or excipients in the formulation. It must not be co-administered with rilpivirine, atazanavir, or nelfinavir due to significant pharmacokinetic interactions causing therapeutic failure of these HIV medications. Patients with severe liver disease (Child-Pugh Class C) require reduced dosing.

Drug Interactions

Esomeprazole interacts with several important drug classes. It can increase plasma levels of drugs metabolised by CYP2C19, including diazepam, phenytoin, citalopram, and cilostazol, potentially increasing their effects and toxicity. Esomeprazole reduces absorption of HIV antiretrovirals (atazanavir, rilpivirine) and antifungals (ketoconazole, itraconazole) that require acidic conditions for dissolution. Coadministration with methotrexate may increase methotrexate toxicity. The interaction with clopidogrel is less pronounced than with omeprazole but remains a consideration in patients on dual antiplatelet therapy. Vitamin B12 absorption may be impaired with long-term use due to reduced acid-dependent cleavage of vitamin B12 from dietary proteins.

Side Effects

Common: Headache, abdominal pain, diarrhoea, nausea, and flatulence. These are generally mild and often resolve within the first few weeks of treatment as the body adjusts.

Uncommon: Dizziness, dry mouth, peripheral oedema, insomnia, and elevated hepatic transaminases.

Rare but important: Hypomagnesaemia — long-term PPI use (usually more than 1 year) can deplete body magnesium stores, causing symptoms ranging from fatigue and muscle weakness to severe neuromuscular dysfunction, cardiac arrhythmias, and seizures. Serum magnesium should be checked before initiating long-term esomeprazole and periodically thereafter. Clostridium difficile infection risk is increased with long-term acid suppression. Bone fracture risk (hip, spine, wrist) with long-term high-dose use — patients should ensure adequate calcium and vitamin D intake. Interstitial nephritis — a rare but serious immune-mediated reaction requiring prompt drug cessation. Subacute cutaneous lupus erythematosus has been reported with all PPIs. Vitamin B12 deficiency with prolonged use. Fundic gland polyps.

Special Populations

Pregnancy (Category B): Animal studies show no foetal harm, but adequate human data are lacking. Esomeprazole should be used in pregnancy only when clearly necessary. Non-pharmacological measures (dietary modification, positional therapy) should be optimised first.

Breastfeeding: Esomeprazole is likely excreted in breast milk; however, no adverse effects have been documented in nursing infants from human studies. Risk-benefit assessment is recommended.

Paediatric use: Espra 40mg is not generally recommended for children under 12 unless specifically indicated and supervised by a paediatric gastroenterologist. The junior formulation (Nexpro Junior Granules) contains esomeprazole 10mg for appropriate paediatric dosing.

Elderly: No dose adjustment required. However, monitor for hypomagnesaemia, bone density, and C. difficile infection more vigilantly in older patients on chronic PPI therapy.

Storage

Store below 25°C in a dry place, away from direct sunlight and moisture. Keep in original packaging until use. Do not store in bathrooms. Keep all medications out of reach of children and pets.

Frequently Asked Questions

Q: Is esomeprazole stronger than omeprazole?
A: Clinical trials have demonstrated that esomeprazole 40mg provides statistically superior acid suppression and higher rates of erosive oesophagitis healing compared to omeprazole 20mg, particularly in patients with severe disease. This is largely attributable to its higher bioavailability as the pure S-enantiomer.

Q: Can I take Espra 40mg at night?
A: PPIs are most effective when taken 30–60 minutes before a meal, as meal stimulation activates newly synthesised proton pumps that are susceptible to PPI inhibition. Morning pre-meal dosing is recommended for most patients. If nocturnal symptoms are problematic, discuss twice-daily dosing with your doctor.

Q: How long can I safely take esomeprazole?
A: Duration depends on the underlying condition. Short-term use (4–8 weeks) is appropriate for acute oesophagitis. Long-term use is medically justified for ZES, severe GERD, Barrett’s oesophagus, and high-risk patients on NSAIDs, but requires regular medical review, the lowest effective dose, and monitoring for complications.

Q: What should I do if I experience severe diarrhoea while taking Espra 40mg?
A: Severe or persistent diarrhoea may indicate C. difficile infection, which is more common with long-term PPI use. Stop the medication and seek medical attention promptly if diarrhoea is severe, watery, or associated with fever or blood.

Important Medical Disclaimer

This product information page is created for educational purposes and is intended to provide accurate, evidence-based information to patients and healthcare professionals. It is not a substitute for professional medical advice, diagnosis, or treatment from a qualified physician or pharmacist. Drug therapy decisions must always be individualised based on the patient’s full clinical picture, comorbidities, and complete medication list. This content adheres to YMYL (Your Money Your Life) standards and has been developed with reference to prescribing information approved by regulatory authorities and peer-reviewed clinical pharmacology literature.